ONO Pharmaceutical Nears Key Readout in Lung Cancer Combo Trial With Tagrisso

ONO Pharmaceutical Co (OPHLF) announced an update on their ongoing clinical study.

The phase I study ONO-7475-03 tests ONO-7475 with AstraZeneca’s Tagrisso (osimertinib) in advanced EGFR‑mutated non-small cell lung cancer. The goal is to see if this combo is safe and tolerable as a first-line option in patients who cannot receive intensive radiation, which could open a new path in a key lung cancer niche.

The trial uses once-daily ONO-7475 with once-daily osimertinib mesylate. ONO-7475 is an oral small-molecule drug being explored to boost the effect of standard EGFR therapy, while osimertinib is already the leading targeted drug for EGFR-positive lung cancer.

This is an interventional phase I trial with one treatment arm and no placebo group. It is open-label and non-randomized, so all patients know what they are getting and the main focus is treatment safety and dosing rather than head-to-head comparisons.

The study was first submitted on 24 July 2024, marking its formal registration and disclosure. The latest update was filed on 11 March 2026, signaling that the sponsor has refreshed key details and that investors should watch for top-line data in the next news cycle.

The trial is listed as completed, which means patient dosing and follow-up are finished and analysis is underway. While no results are posted yet, this timing increases the odds of near-term news flow that could move ONO’s shares and shape views on its pipeline value.

For investors, the main angle is strategic rather than near-term revenue, as a positive safety profile could justify larger combo trials with Tagrisso in a high-value lung cancer segment. Any sign that ONO-7475 enhances efficacy without major new risks would support ONO’s R&D story and may prompt investors to reassess its competitive stance versus other oncology developers.

At the same time, AstraZeneca’s entrenched position with Tagrisso and competing EGFR and resistance-pathway assets worldwide mean ONO still faces a crowded field. The update keeps ONO in the conversation around next-wave EGFR combinations, but the ultimate market impact will hinge on data quality and partnering terms.

The ONO-7475-03 study is now completed and recently updated, and further details are available on the ClinicalTrials.gov portal.

To learn more about OPHLF’s potential, visit the ONO Pharmaceutical Co drug pipeline page.